Kyverna Therapeutics Enters into a Collaboration Agreement with Stanford University to Evaluate KYV-101 for the Treatment of Multiple Sclerosis
Shots:
- Kyverna Therapeutics signed a collaboration agreement with the Stanford University to allow the evaluation of KYV-101 in a P-I clinical trial evaluating patients (n=12) with non-relapsing and progressive forms of multiple sclerosis
- This study will add to the company’s ongoing P-II (KYSA-7) clinical trial in MS and other KYSA clinical trial in rheumatological & neurological autoimmune disorders. Additionally, the company will form parallel agreements to support the development of KYV-101 in MS patients
- KYV-101 is a fully human anti-CD19 CAR T-cell therapy developed for the treatment of B-cell driven autologous diseases. The company further expects to extend the development of KYV-101 into additional indications
Ref: PRNewswire | Image: Kyverna Therapeutics
Related News:- Kyverna Therapeutics Receives the US FDA’s IND Clearance to Initiate the P-I/II Study of KYV-101 for the Treatment of Scleroderma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
